Table 2.
Patient Demographics and Characteristics.
| Background | Advanced PCa (n = 37) |
Non-advanced PCa (n = 66) |
|---|---|---|
| Median age, years (range) | 68 (53–81) | 72 (40–86) |
| Living with family/alone | 34/3 | 63/3 |
| Work status | ||
| Non-working | 22 | 49 |
| Working | 15 | 14 |
| Other | 0 | 3 |
| Hospital type | ||
| Cancer center | 4 | 1 |
| University | 10 | 14 |
| General hospital | 21 | 42 |
| Practitioner | 2 | 9 |
| Perceived access to hospital | ||
| Good | 20 | 25 |
| Acceptable | 14 | 33 |
| Poor | 3 | 8 |
| Mean PSA value, ng/ml (± SD) | 25.8 (± 98.8) (n = 35) | 0.7 (± 2.6) (n = 57) |
| Metastatic status | ||
| Positive | 31 | 0 |
| Negative | 5 | 61 |
| Unknown | 1 | 5 |
| Mean FACT-P score (± SD) | 99.8 (± 20.4) | 114.2 (± 14.2) |
| Medication, n | ||
| LHRH agonists | 25 | 42 |
| Bicalutamide | 19 | 45 |
| Dexamethasone | 5 | |
| Docetaxel | 4 | |
| Flutamide | 3 | |
| Abiraterone acetate | 2 | |
| Enzalutamide | 1 | |
| Prednisolone | 1 | |
| Other | 1 | |
Note. FACT-P = Functional Assessment of Cancer Therapy-Prostate; LHRH = luteinizing hormone-releasing hormone; PSA = prostate-specific antigen; PCa = prostate cancer.